29 October 2024NewsPatentsMithu Sherin Director of Intellectual Property ALX Oncology, David Diamond VP & Head of Intellectual Property Capstan Therapeutics, Alexander Trimble Member Mintz, Siegmund Gutman Chair Life Sciences Litigation Practice Mintz
WATCH: Beyond the obvious: novelty, non-obviousness, and the inventive step in polymorph patents and beyond
In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step. This panel will examine the complexities of these fundamental patent requirements in practice, with a special focus on polymorph patents and related areas. We'll explore how recent developments and legal decisions impact innovators and the IP landscape.
The recent Federal Circuit decision in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. and its implications for obviousness issues in polymorph patents
Strategies for evaluating novelty in polymorph and other inventions
Navigating the non-obviousness criteria for polymorphs from both prosecution and litigation perspectives
Examining the 'inventive step' requirement for polymorphs at the USPTO, EPO, and other key jurisdictions
Drawing analogies between polymorph patent strategies and biologics patent issues
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
12 February 2025 The UK’s first-ever IP compulsory mediation order resolved the football club’s trademark dispute, increasing the value of ‘problem solving’ tactics over litigation, finds Muireann Bolger.